Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarantus Bioscience Holdings Inc Reports Positive Results On MANF Neuroprotective Properties Demonstrated In Preclinical Study In China


Wednesday, 19 Jun 2013 07:30am EDT 

Amarantus Bioscience Holdings Inc announced positive neuroprotective properties for the Company`s MANF therapeutic were reported in a preclinical research study conducted by the Department of Orthopaedics at Qilu Hospital of Shandong University, in Jinan, China. Specifically, a published abstract of the study concluded, These findings demonstrate that MANF shows the potential to alleviate cell damage and inflammation in rat primary astrocytes by suppressing ER (endoplasmic reticulum) stress, indicating that MANF plays an important role in astrocyte inflammation and functioning and may suggest a promising strategy for neuroprotection in the central nervous system. The findings from the study at Shandong University are consistent with the results obtained in own research with MANF on rat models for Parkinson`s disease, which were reported in March 2013. The independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson`s disease. The Company will continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA. 

Company Quote

0.1834
-0.0101 -5.22%
30 Jul 2014